Response to primary canine core vaccination in 10-month-old seronegative dogs treated with three times the recommended therapeutic dose of Ilunocitinib tablets (Zenrelia™)

Response to primary canine core vaccination in 10-month-old seronegative dogs treated with three times the recommended therapeutic dose of Ilunocitinib tablets (Zenrelia™)

Abstract Background This study was designed to test the effect of a novel JAK inhibitor, ilunocitinib, on the response to modified live and inactivated vaccines when given at three times the label dose to healthy, vaccine-naive, seronegative, juvenile (10-month-old) purpose-bred research dogs. Durin...

Full description

Saved in:
Bibliographic Details
Main Authors: Genevieve M. Fent, Simona Despa, Les Gabor, Madison Earll, Erin E. McCandless, Sandra O’Kelley, Jared R. Patch, Jonathan Snyder, Stephen King
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Veterinary Research
Subjects:
JAK inhibitor
Vaccination
Ilunocitinib
Zenrelia
Coccidiosis
Immune response
Online Access:https://doi.org/10.1186/s12917-025-04896-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items